Global Markets for Vaccine Technologies

Published - Jan 2017| Analyst - Shalini Shahani Dewan| Code - PHM014F
Global Markets for Vaccine Technologies
Single User License: $1975 Member Price: FREE

Report Highlights

The global market for vaccine technologies reached $33.3 billion in 2016 and should reach $45.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 6.3% from 2016 to 2021.

Report Includes

  • An overview of the global market for human and animal (veterinary) vaccines
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021
  • A review of vaccine technology and its challenges, innovations, opportunities and regulatory hurdles
  • Evaluations of market sizes and developments for vaccine classes (prophylactic and therapeutic), vaccine types (inactivated, conjugate, attenuated, recombinant vector, subunit, toxoid, combination and dendritic cells), vaccine end-users (humans and animals) and disease indications (infectious, cancer and allergy)
  • Examination of industry environment, strategies, market influences and driving forces
  • Identification of regional market sizes, prices and trends
  • Analysis of relevant patents
  • Profiles of major players in the industry

Report Scope

The scope of this study entails the current market for human and animal vaccines. The report also includes regulatory aspects, current and developing technologies, market projections and market share. An analysis of patents, clinical trials, innovations and opportunities, as well as the latest trends is also discussed.

Sales data for the global and regional markets were corroborated for the present and forecasted values based on statistical analysis. Regions are categorized into the United States, Europe and the emerging markets, which include India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand. The application of vaccines in various diseases is discussed from both a commercial and R&D perspective.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Jul-2013| Analyst - Shalini Shahani Dewan| Code - PHM014E

Report Highlights

Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.

Report Includes

  • An overview of the global market for human and animal (veterinary) vaccines and related vaccine technologies.
  • Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
  • Examination of current and future strategies within the human and animal (veterinary) vaccines markets, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines.
  • A breakdown of the seven major categories of vaccines broken down by market shares belonging to leading manufacturers and/or suppliers.
  • Discussion of human and animal (veterinary) vaccines as to their prophylactic or therapeutic use, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, and travel vaccines.

Published - Jan-2011| Analyst - Shalini Shahani Dewan| Code - PHM014D

Report Highlights

Global sales of human and animal vaccines reached approximately $25.2 billion in 2009. The market is expected to rise at a compound annual growth rate (CAGR) of 17.9% to reach $64.2 billion by 2015.

Published - Jan-2008| Analyst - Vanita Khetan| Code - PHM014C

Report Highlights

  • The global market for vaccines is expected to reach $22.4 billion by the end of 2008. It should reach $36.3 billion by 2013, a com¬pound annual growth rate (CAGR) of nearly 11%.
  • Although pediatric vaccines traditionally have had the largest share of the market, adult and therapeutic vaccines will likely usurp this position in the near future.
  • Patent activity has heightened to an almost frenzied level over the study period, with as many as 250 each year for 2006 and 2007.
Published - Sep-2001| Analyst - Lynn Gray| Code - PHM014B

Report Highlights

  • The total worldwide market for prophylactic and therapeutic vaccines is estimated to be $5.8 billion in 2001.
  • Growing at an average annual rate (AAGR) of 11.6%, this market is expected to approach $10 billion in 2006.
  • Pediatric prophylactic vaccines make up 58% of the current market, but will show the slowest growth, at an AAGR of 8.7% through 2006.
  • Adult prophylactic vaccines are the second largest group with sales of nearly $2.4 billion in 2001 and are expected to rise at an AAGR of 10.1% to more than $3.8 billion in 2006.
  • Therapeutic vaccines will feature growth of more than 100% on average per year through the period, but by 2006 will still make up only 10.5% of the market.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report